Literature DB >> 18005275

Flow cytometric assays for quantifying activated ovine platelets.

Carl A Johnson1, Trevor A Snyder, Joshua R Woolley, William R Wagner.   

Abstract

Ovines are a common animal model for preclinical evaluation of cardiovascular devices including heart valves, endovascular grafts, and ventricular assist devices. Biocompatibility is essential to the success of these devices; however, tools to assess biocompatibility in ovines are limited. To address this need, antibodies that bind to activated human and bovine platelets and annexin V protein were evaluated for potential cross-reactivity to activated ovine platelets. These candidate markers were incubated with stimulated and quiescent ovine whole blood, and binding to platelets was quantified by flow cytometry. Several antihuman CD62P antibodies including one polyclonal antibody, three monoclonal antibodies, and annexin V selectively bound to activated ovine platelets. An assay to quantify platelet microaggregates was also developed. The availability of assays to quantify ovine platelet activation can increase the quality of biocompatibility data obtainable during preclinical development of artificial organs in the ovine model, potentially aiding in the evaluation of design refinements to enhance device biocompatibility.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18005275      PMCID: PMC3285490          DOI: 10.1111/j.1525-1594.2007.00498.x

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  27 in total

1.  Implantation of the VentrAssist Implantable Rotary Blood Pump in sheep.

Authors:  Natalie L James; Anita L van der Meer; Glenn A Edwards; Samuel R Snelling; John D Begg; Donald S Esmore; John C Woodard
Journal:  ASAIO J       Date:  2003 Jul-Aug       Impact factor: 2.872

2.  Biochemical characterization of antigens detected with anti-platelet monoclonal antibodies.

Authors:  A Mateo; J Perez de la Lastra; A Moreno; R Dusinsky; F Bilka; M Simon; L Horovska; D Llanes
Journal:  Vet Immunol Immunopathol       Date:  1996-08       Impact factor: 2.046

3.  Ruminant cluster CD41/CD61.

Authors:  A Mateo; C O Pintado; J Perez de la Lastra; R Dusinsky; M Simon; J Naessens; D Llanes
Journal:  Vet Immunol Immunopathol       Date:  1996-08       Impact factor: 2.046

4.  Platelet activation studies with anti-CD41/61 monoclonal antibodies.

Authors:  A Mateo; J M Perez de la Lastra; J J Garrido; D Llanes
Journal:  Vet Immunol Immunopathol       Date:  1996-08       Impact factor: 2.046

5.  Effect of strenuous exercise on platelet activation state and reactivity.

Authors:  A S Kestin; P A Ellis; M R Barnard; A Errichetti; B A Rosner; A D Michelson
Journal:  Circulation       Date:  1993-10       Impact factor: 29.690

Review 6.  Platelet activation by thrombin can be directly measured in whole blood through the use of the peptide GPRP and flow cytometry: methods and clinical applications.

Authors:  A D Michelson
Journal:  Blood Coagul Fibrinolysis       Date:  1994-02       Impact factor: 1.276

7.  Role of activation-dependent platelet membrane glycoproteins in development of subacute occlusive coronary stent thrombosis.

Authors:  M Gawaz; F J Neumann; I Ott; A May; S Rüdiger; A Schömig
Journal:  Coron Artery Dis       Date:  1997 Mar-Apr       Impact factor: 1.439

8.  Binding of annexin V/placental anticoagulant protein I to platelets. Evidence for phosphatidylserine exposure in the procoagulant response of activated platelets.

Authors:  P Thiagarajan; J F Tait
Journal:  J Biol Chem       Date:  1990-10-15       Impact factor: 5.157

9.  Platelet activation and aggregation profile in prolonged external ventricular support.

Authors:  Rémi Houël; Elisabeth Mazoyer; Bernadette Boval; Mathias Kirsch; Emmanuelle Vermès; Ludovic Drouet; Daniel Y Loisance
Journal:  J Thorac Cardiovasc Surg       Date:  2004-08       Impact factor: 5.209

10.  Platelet function in acute myocardial infarction treated with direct angioplasty.

Authors:  M Gawaz; F J Neumann; I Ott; A Schiessler; A Schömig
Journal:  Circulation       Date:  1996-01-15       Impact factor: 29.690

View more
  15 in total

1.  The national heart, lung, and blood institute pediatric circulatory support program: a summary of the 5-year experience.

Authors:  J Timothy Baldwin; Harvey S Borovetz; Brian W Duncan; Mark J Gartner; Robert K Jarvik; William J Weiss
Journal:  Circulation       Date:  2011-03-22       Impact factor: 29.690

2.  Biocompatibility Assessment of the CentriMag-Novalung Adult ECMO Circuit in a Model of Acute Pulmonary Hypertension.

Authors:  Venkat Shankarraman; Ergin Kocyildirim; Salim E Olia; Marina V Kameneva; Ryan J Dzadony; Timothy M Maul; Marc A Simon; Hunter C Champion; William R Wagner; Christian A Bermudez
Journal:  ASAIO J       Date:  2014 Jul-Aug       Impact factor: 2.872

3.  Real time visualization and characterization of platelet deposition under flow onto clinically relevant opaque surfaces.

Authors:  Megan A Jamiolkowski; Joshua R Woolley; Marina V Kameneva; James F Antaki; William R Wagner
Journal:  J Biomed Mater Res A       Date:  2014-05-06       Impact factor: 4.396

4.  Biocompatibility assessment of the first generation PediaFlow pediatric ventricular assist device.

Authors:  Carl A Johnson; Stijn Vandenberghe; Amanda R Daly; Joshua R Woolley; Shaun T Snyder; Josiah E Verkaik; Sang-Ho Ye; Harvey S Borovetz; James F Antaki; Peter D Wearden; Marina V Kameneva; William R Wagner
Journal:  Artif Organs       Date:  2011-01       Impact factor: 3.094

5.  Platelet activation after implantation of the Levitronix PediVAS in the ovine model.

Authors:  Carl A Johnson; Venkat Shankarraman; Peter D Wearden; Ergin Kocyildirim; Timothy M Maul; John D Marks; J Scott Richardson; Barry N Gellman; Harvey S Borovetz; Kurt A Dasse; William R Wagner
Journal:  ASAIO J       Date:  2011 Nov-Dec       Impact factor: 2.872

6.  Preoperative liver dysfunction influences blood product administration and alterations in circulating haemostatic markers following ventricular assist device implantation.

Authors:  Joshua R Woolley; Robert L Kormos; Jeffrey J Teuteberg; Christian A Bermudez; Jay K Bhama; Kathleen L Lockard; Nicole M Kunz; William R Wagner
Journal:  Eur J Cardiothorac Surg       Date:  2014-05-07       Impact factor: 4.191

7.  Simple surface modification of a titanium alloy with silanated zwitterionic phosphorylcholine or sulfobetaine modifiers to reduce thrombogenicity.

Authors:  Sang-Ho Ye; Carl A Johnson; Joshua R Woolley; Hironobu Murata; Lara J Gamble; Kazuhiko Ishihara; William R Wagner
Journal:  Colloids Surf B Biointerfaces       Date:  2010-04-24       Impact factor: 5.268

8.  Surface modification of a biodegradable magnesium alloy with phosphorylcholine (PC) and sulfobetaine (SB) functional macromolecules for reduced thrombogenicity and acute corrosion resistance.

Authors:  Sang-Ho Ye; Yong-Seok Jang; Yeo-Heung Yun; Venkat Shankarraman; Joshua R Woolley; Yi Hong; Lara J Gamble; Kazuhiko Ishihara; William R Wagner
Journal:  Langmuir       Date:  2013-06-18       Impact factor: 3.882

9.  Covalent surface modification of a titanium alloy with a phosphorylcholine-containing copolymer for reduced thrombogenicity in cardiovascular devices.

Authors:  Sang-Ho Ye; Carl A Johnson; Joshua R Woolley; Trevor A Snyder; Lara J Gamble; William R Wagner
Journal:  J Biomed Mater Res A       Date:  2009-10       Impact factor: 4.396

10.  Surface modification of a titanium alloy with a phospholipid polymer prepared by a plasma-induced grafting technique to improve surface thromboresistance.

Authors:  Sang Ho Ye; Carl A Johnson; Joshua R Woolley; Heung-Il Oh; Lara J Gamble; Kazuhiko Ishihara; William R Wagner
Journal:  Colloids Surf B Biointerfaces       Date:  2009-07-07       Impact factor: 5.268

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.